Name (Synonyms) | Correlation | |
---|---|---|
drug2739 | Stellate Ganglion Block Wiki | 1.00 |
drug409 | Biological collection (patients co infected HIV Sras-CoV-2) Wiki | 0.71 |
drug2300 | Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19) Wiki | 0.71 |
drug296 | Auto-questionnaires (patients co infected HIV Sras-CoV-2) Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.07 |
D055371 | Acute Lung Injury NIH | 0.07 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.07 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.
Description: Adverse events that can atleast unlikely be attributed to SGB
Measure: Adverse events related to SGB Time: 3 MonthsDescription: All adverse events related to COVID-19
Measure: All Adverse events Time: 3 MonthsDescription: Death due to any cause
Measure: Death Time: 3 MonthsDescription: Change from baseline (descibed as last ratio prior to procedure)
Measure: PaO2/FiO2 or SpO2/FiO2(SF) ratio change from baseline Time: 3 MonthsDescription: change from last imaging data obtained prior to SGB procedure
Measure: Radiographic criteria Time: 3 MonthsThis study will establish the safety and efficacy of using stellate ganglion blocks in patients with ARDS due to COVID-19 disease.
Description: Adverse events related to SGB.
Measure: Evaluate the safety of a new modified stellate ganglia block (SGB) in ARDS Time: 3 monthDescription: All adverse events.
Measure: Evaluate the efficacy of a new modified stellate ganglia block (SGB) in ARDS Time: 3 month